ST003

ST003 is an early-stage therapeutic candidate being developed by Santo Therapeutics (Hangzhou Santo Biotechnology). While specific details regarding its biological target and primary indication have not been fully disclosed, it is part of a pipeline focused on advancing in vivo gene therapies and in vivo CAR-T cell therapies for oncology and rare genetic disorders. The candidate is designed to leverage the company's proprietary fifth-generation lentiviral vector platform, STLenti®, which is engineered for high targeting accuracy and safety in delivering genetic material directly to tissues. Santo Therapeutics' broader research focus includes conditions such as neurofibromatosis type 2 (NF2), bladder cancer, malignant pleural mesothelioma, and glioblastoma, with ST003 likely targeting one of these high-unmet-need areas.